Table III.
The Odds of Reporting Standard Improvements in Patient Reported Outcomes, by treatment group
| Placebo N (%) | Adalimumab N (%) | Phototherapy N (%) | Adalimumab vs Placebo OR (95% Cl) | Phototherapy vs Placebo OR (95% Cl) | Phototherapy vs Adalimumab OR (95% Cl) | |
|---|---|---|---|---|---|---|
| “No Impairment” in Quality of Lifea | ||||||
| DLQIa | 3 (10.0) | 8 (25.0) | 14 (45.16%) | 3.00 (0.71, 12.62) | 7.41 (1.85,29.66) | 2.47 (0.85,7.19) |
| EQ-5D-3Lb | ||||||
| Mobility Dimension | 25 (83.33) | 26 (81.25) | 26 (83.87) | 0.87 (0.23, 3.20) | 1.04 (0.27,4.03) | 1.20 (0.33,4.43) |
| Self-care Dimension | 27 (90.0) | 31 (96.88) | 29 (93.55) | 3.44 (0.34, 35.09) | 1.61 (0.25, 10.39) | 0.47 (0.04, 5.42) |
| Activity Dimension | 21 (70.0) | 25 (78.12) | 27 (87.10) | 1.53 (0.49,4.81) | 2.89 (0.78, 10.71) | 1.89 (0.49,7.24) |
| Pain Dimension | 7 (23.33) | 15 (46.88) | 20 (64.52) | 2.90 (0.97, 8.66) | 5.97 (1.95,18.33) | 2.06 (0.75, 5.67) |
| Anxiety Dimension | 17 (56.67) | 20 (62.50) | 23 (74.19) | 1.27 (0.46,3.52) | 2.20 (0.75, 6.48) | 1.73 (0.59,5.06) |
| Achievement of the Minimal Clinically Important Differenceb | ||||||
| DLQI | 13 (43.33) | 22 (68.75) | 27 (87.1) | 2.88 (1.02, 8.17) | 8.83 (2.47, 31.57) | 3.07 (0.85, 11.13) |
| EQ-5D Index | 6 (20.00) | 12 (37.50) | 22 (70.97) | 2.40 (0.76, 7.55) | 9.78 (2.99, 31.95) | 4.07 (1.42, 11.70) |
a
Univariable logistic regression comparing the odds of reporting no effect of quality of life (<2) vs any effect (≥2) for DLQI and no problem (≤1) vs any problem (>1) for each of the EQ-5D dimensions
b
Univariable logistic regression comparing the odds of achieving MCID for DLQI (4-point decrease in DLQI score at week 12) and EQ-5D Index (0.05-point increase in EQ-5D Index value at week 1